Plaque

NextFlex Announces 2024 Fellows Awards for Five Outstanding Recipients

Retrieved on: 
Thursday, March 28, 2024
Hardware, IOT (Internet of Things), Chemicals, Plastics, Automotive Manufacturing, Aerospace, Manufacturing, Government Technology, Technology, Audio, Video, Defense, Military, Science, Telecommunications, Engineering, Research, Manufacturing USA, Tissue engineering, General Electric, USMC, Electrical engineering, Laser, Education, Madhu, Honeywell, Electronics, BD (company), AFRL, Plaque, NASA, STEM, SME, Miniaturization, Sigma, Printed electronics, Multimedia, Lighting, NRO, DARPA, Navy, Air Products, Management

NextFlex®, America's Hybrid Electronics Manufacturing Institute, presented the annual NextFlex Fellow Awards to five deserving individuals in recognition of their exceptional commitment to advanced manufacturing and the additive hybrid electronics member community.

Key Points: 
  • NextFlex®, America's Hybrid Electronics Manufacturing Institute, presented the annual NextFlex Fellow Awards to five deserving individuals in recognition of their exceptional commitment to advanced manufacturing and the additive hybrid electronics member community.
  • A NextFlex Fellow demonstrates leadership and subject matter expertise in support of the NextFlex mission.
  • View the full release here: https://www.businesswire.com/news/home/20240328483614/en/
    Left photo: 2024 Fellows Award recipients are presented with plaques by the NextFlex Co-Executive Directors.
  • These outstanding trailblazers exemplify what’s best about our member community as they help drive the NextFlex mission forward.

Pragmatic Welcomes HRH The Princess Royal to Pragmatic Park for the Opening of the UK's First 300mm Semiconductor Wafer Manufacturing Facility

Retrieved on: 
Wednesday, March 27, 2024
Wearables, Mobile Technology, Other Manufacturing, Environment, Technology, Semiconductor, Other Technology, Manufacturing, Green Technology, IOT (Internet of Things), HRH, Intelligence, UKIB, Internet of things, Recycling, Pension, Princess Royal, Bank, News, Plaque, Carbon, Simon Little, Water, Ecosystem, Avery Dennison, Multimedia, Silicon, Industrial design

Today, Pragmatic Semiconductor was honoured to welcome HRH The Princess Royal to officially open the UK’s first 300mm semiconductor wafer fabrication line (fab) at Pragmatic Park in Durham.

Key Points: 
  • Today, Pragmatic Semiconductor was honoured to welcome HRH The Princess Royal to officially open the UK’s first 300mm semiconductor wafer fabrication line (fab) at Pragmatic Park in Durham.
  • The advanced manufacturing facility produces chips based on Pragmatic’s innovative and unique flexible integrated circuit technology.
  • HRH The Princess Royal was hosted by David Moore, CEO, Pragmatic Semiconductor, with a tour of the clean room and facilities, followed by an unveiling of a site plaque to mark the occasion.
  • Pragmatic Park has capacity to host up to nine fabrication lines, each capable of producing billions of chips per year.

Robbins LLP Urges VTYX Investors with Large Losses to Contact the Firm Before April 30, 2024, for Information About Their Rights

Retrieved on: 
Monday, March 18, 2024
Class Action Lawsuit, Professional Services, Legal, Plaque, IPO, Psoriasis, Inflammation, LLP, News, Pharmaceutical industry

Ventyx is a clinical-stage biopharmaceutical company that develops small molecule product candidates to address a range of inflammatory diseases.

Key Points: 
  • Ventyx is a clinical-stage biopharmaceutical company that develops small molecule product candidates to address a range of inflammatory diseases.
  • The Company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.
  • In 2022, Ventyx initiated a Phase 2 clinical trial of VTX958 for the treatment of moderate to severe plaque psoriasis (the “Phase 2 SERENITY Trial”).
  • For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

Bristol Myers Squibb and Ted Danson Empower Those with Plaque Psoriasis to Take Action in “SO, Have You Found It?” Campaign

Retrieved on: 
Tuesday, March 19, 2024
Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Psoriasis, Partnership, Patient, Neuroscience, Travel, Dermatology, Plaque, Bristol Myers Squibb, Humour, DSM-IV codes, Empowerment, System, Skin, Multimedia, FDA, Pharmaceutical industry

Award-winning actor Ted Danson, who lives with plaque psoriasis, teams up with Bristol Myers Squibb for the inspiring “ SO, Have You Found It?

Key Points: 
  • Award-winning actor Ted Danson, who lives with plaque psoriasis, teams up with Bristol Myers Squibb for the inspiring “ SO, Have You Found It?
  • View the full release here: https://www.businesswire.com/news/home/20240315988620/en/
    Actor Ted Danson and SOTYKTU patient Emily both living with moderate to severe plaque psoriasis.
  • (Photo: Bristol Myers Squibb)
    “Navigating plaque psoriasis is both deeply personal and often challenging for many patients,” acknowledged Carlos Dortrait, senior vice president and general manager of U.S. Immunology and Neuroscience at Bristol Myers Squibb.
  • Many with plaque psoriasis find themselves altering their lifestyles, sometimes avoiding social situations and personal connections.

Iliac Stent Market Size, Share & Trends Analysis Report 2024: A USD 1.53 Billion Market by 2030, Projected to Grow at a CAGR of 5.8% from 2024 to 2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Health, Surgery, Medical Devices, Hospital, NCBI, Obesity, NMPA, Growth, Prevalence, Peripheral artery disease, Getinge Group, Incidence, Patient, Evaluation, PAD, Plaque, Google Images, National Medical Products Administration, Iliac artery, USD, Marketing, Pharmaceutical industry

The global iliac stent market size is expected to reach USD 1.53 billion by 2030, projected to grow at a CAGR of 5.8% from 2024 to 2030.

Key Points: 
  • The global iliac stent market size is expected to reach USD 1.53 billion by 2030, projected to grow at a CAGR of 5.8% from 2024 to 2030.
  • Furthermore, the growing prevalence of peripheral artery disease (PAD) is expected to propel iliac stents market growth.
  • In 2023, North America held the largest share in the iliac stents market, with a revenue share of 43.7%.
  • Hospitals serve as referral centers where patients receive comprehensive care, including diagnostic imaging, medical management, and interventional procedures like iliac stent placement

SourceNow, First VMS Company in the World to Be Finalizing B Corp Certification: A Milestone for Sustainable Business Practices

Retrieved on: 
Wednesday, March 13, 2024
Software, Human Resources, Environmental, Social and Governance (ESG), Data Management, Professional Services, Technology, Logistics, Supply Chain Management, Transport, Certification, Vendor management system, Environment, Recycling, Professional corporation, Social responsibility, Plaque, Multimedia, Movement, Nursing

This prestigious certification underscores SourceNow’s dedication to not just being the best in the world, but being the best for the world.

Key Points: 
  • This prestigious certification underscores SourceNow’s dedication to not just being the best in the world, but being the best for the world.
  • The certification process is rigorous, with companies required to demonstrate their positive impact on their workers, customers, community, and the environment.
  • “We believe in doing business differently, in a way that fosters community, protects the environment, and creates long-term value for all stakeholders involved.
  • For more information about SourceNow and its sustainability initiatives, SourceNow will be releasing an education webpage on its website to provide additional resources and information.

VTYX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ventyx Biosciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Tuesday, March 12, 2024
Class Action Lawsuit, Professional Services, Legal, Psoriasis, Defendant, News, IPO, Inflammation, Plaque, Prospectus, Complaint, Court, Person, Pharmaceutical industry

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Ventyx Biosciences, Inc. (“Ventyx” or “the Company”) (NASDAQ: VTYX) and certain of its officers.

Key Points: 
  • Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Ventyx Biosciences, Inc. (“Ventyx” or “the Company”) (NASDAQ: VTYX) and certain of its officers.
  • Ventyx is a clinical-stage biopharmaceutical company that develops small molecule product candidates to address a range of inflammatory diseases.
  • The Company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Innovating "Treadmill Exercise Test AI-Assisted Interpretation System," CMUH(Taiwan) Timely Saves More Patients with Severe Myocardial Infarction

Retrieved on: 
Tuesday, April 2, 2024
Depression, Thrombosis, Myocardial infarction, Sudden death, Cardiovascular disease, Exercise, Survival, Coronary artery disease, ECG, Hyperlipidemia, Patient, Palpitations, Angina, Cancer, AI, Death, Moyamoya disease, Chronic pain, Plaque, Diet, Receiver, Smoking, Cardiac catheterization, Stenosis, Oxygen, Heart, Atherosclerosis, Rupture, Ministry, Duke, Vascular occlusion, CAD

To address this issue, China Medical University Hospital (CMUH) AI Center successfully developed the "Treadmill Exercise Test AI-Assisted Interpretation System" which was trained with nearly a thousand treadmill ECG, in patients with coronary arterystenosisover 70% shown on their coronary angiography.

Key Points: 
  • To address this issue, China Medical University Hospital (CMUH) AI Center successfully developed the "Treadmill Exercise Test AI-Assisted Interpretation System" which was trained with nearly a thousand treadmill ECG, in patients with coronary arterystenosisover 70% shown on their coronary angiography.
  • The program also utilizes ten measured features and two derived features including maximal work output and peak heart rate to determine the severity of coronary artery stenosis.
  • Generally, coronary heart disease in patients of middle or senior age is presented as angina or myocardial infarction and is one of the primary causes of sudden death."
  • Dr. Wu stated, "Coronary artery stenosis is a multi-factorial condition related to smoking, advanced age, diabetes hypertension and hyperlipidemia.

Heart & Lung Health selects Caristo Diagnostics AI technology to provide early diagnosis of coronary artery disease UK-wide

Retrieved on: 
Tuesday, March 19, 2024
Diagnosis, Lung cancer, Chest pain, Information technology, Radiology, Coronary artery disease, Partnership, Risk, University, Patient, Lung, Calcium, National Health Service, NHS, Research, Hospital, RadNet, Artificial intelligence, Death, Plaque, Artery, Mace, CCTA, Heart, HLH, Health, Medical device

OXFORD, England, March 19, 2024 /PRNewswire/ -- Heart & Lung Health (HLH), a UK-wide network of over 110 expert cardiothoracic radiologists, has partnered with Caristo Diagnostics, a leading cardiac disease diagnostics company, to offer the novel CaRi-Heart® AI technology to predict patients' risk of developing potentially fatal coronary artery disease.

Key Points: 
  • OXFORD, England, March 19, 2024 /PRNewswire/ -- Heart & Lung Health (HLH) , a UK-wide network of over 110 expert cardiothoracic radiologists, has partnered with Caristo Diagnostics , a leading cardiac disease diagnostics company, to offer the novel CaRi-Heart® AI technology to predict patients' risk of developing potentially fatal coronary artery disease.
  • Many will undergo a coronary computed tomography angiography (CCTA) scan to diagnose coronary artery disease caused by plaques that narrow or block the arteries that supply blood to the heart.
  • "Early diagnosis and interventions have the potential to significantly improve health outcomes for thousands of patients at risk of coronary artery disease.
  • We are pleased to announce our partnership with Heart & Lung Health, aiming to enhance accessibility to CaRi-Heart technology for patients throughout the UK," said Frank Cheng, CEO of Caristo Diagnostics.

Natural Farm Introduces Traditional Himalayan Yak Cheese: Handcrafted with Care

Retrieved on: 
Monday, March 18, 2024
Amazon, Lactose, Calcium, Milk, Hypertrophy, Plaque, Dog, Allergy, CMO, Animal husbandry

ATLANTA, March 18, 2024 /PRNewswire-PRWeb/ -- Natural Farm, a leading provider of 100% all-natural dog treats, chews, and bones, launched an innovative new product line in February 2024. Yak Cheese Chews are crafted from pure yak and cow milk, using traditional methods that have been passed down through generations.

Key Points: 
  • Natural Farm is delighted to announce the launch of its latest product line within the allergen-friendly category, Himalayan Yak Cheese Chews.
  • Natural Farm is committed to producing innovative, healthy dog treats, and this new product line is a testament to their excellence in the pet products industry.
  • Yak Cheese Chews are crafted from pure yak and cow milk, using traditional methods that have been passed down through generations.
  • For more information on Natural Farm and their Yak Cheese Chews, please visit naturalfarmpet.com or email [email protected] .